Aurobindo Pharma Limited is an Indian pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The companys area of activity includes six major therapeutic/product areas: antibiotics, antiretrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergics. The company markets these products in over 125 countries Its marketing partners include AstraZeneca and Pfizer.Aurobindo Pharma plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars, and novel drug delivery solutions like depot injections, inhalers, patches, and films. It has also set its sights on geographic expansion in new territories like Poland, Italy, Spain, the Czech Republic, Portugal, and France, as the generic drug market in these countries is relatively small.In 2017, Aurobindo Pharma inked a pact to acquire Portugals Generis Farmaceutica SA from Magnum Capital Partners for a consideration of 135 million. It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the Netherlands, Spain, and Belgium. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.